[HTML][HTML] Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma
RJ Verheijden, FH Burgers, JC Janssen… - European Journal of …, 2024 - Elsevier
Background Recent studies indicate an association between immunosuppression for
immune-related adverse events (irAEs) and impaired survival in patients who received …
immune-related adverse events (irAEs) and impaired survival in patients who received …
[HTML][HTML] Frequency, treatment and outcome of immune-related toxicities in patients with immune-checkpoint inhibitors for advanced melanoma: results from an …
F Dimitriou, R Staeger, M Ak, M Maissen, K Kudura… - Cancers, 2021 - mdpi.com
Simple Summary In this study, we investigated the impact of immune-related adverse events
(irAEs) on the survival of advanced melanoma patients treated with immune-checkpoint …
(irAEs) on the survival of advanced melanoma patients treated with immune-checkpoint …
[HTML][HTML] Better late than never: the impact of steroidal treatment on the outcome of melanoma patients treated with immunotherapy
Simple Summary In the era of immunotherapy, advanced melanoma patients have
unprecedentedly higher survival rates. However, the application of immunotherapy may lead …
unprecedentedly higher survival rates. However, the application of immunotherapy may lead …
Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors
K Tyan, J Baginska, M Brainard… - Cancer Immunology …, 2021 - Springer
Abstract Background Immune checkpoint inhibitors (ICIs) often cause immune-related
adverse events (irAEs), most of which are treated with corticosteroids despite evidence …
adverse events (irAEs), most of which are treated with corticosteroids despite evidence …
Preexisting immune‐mediated inflammatory disease is associated with improved survival and increased toxicity in melanoma patients who receive immune …
Background Immune‐related adverse events (irAEs) are common, clinically significant
autoinflammatory toxicities observed with immune checkpoint inhibitors (ICI). Preexisting …
autoinflammatory toxicities observed with immune checkpoint inhibitors (ICI). Preexisting …
The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real‐world, multicenter, retrospective study
S Lev‐Ari, M Serzan, T Wu, A Ip, L Pascual… - Cancer, 2023 - Wiley Online Library
Background Immune‐related adverse events (irAEs) associated with immune checkpoint
inhibitors (ICIs) are often managed via immunosuppressive agents (ISAs); however, their …
inhibitors (ICIs) are often managed via immunosuppressive agents (ISAs); however, their …
[HTML][HTML] The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies
CE Wu, CK Yang, MT Peng, PW Huang, CF Chang… - BMC cancer, 2020 - Springer
Background The association between immune-related adverse events (irAEs) and survival
outcomes in patients with advanced melanoma receiving therapy with immune checkpoint …
outcomes in patients with advanced melanoma receiving therapy with immune checkpoint …
[HTML][HTML] Effect of glucocorticoids for the management of immune-related adverse events on outcome in melanoma patients treated with immunotherapy—a …
FC Svedman, M Liapi, A Månsson-Broberg… - Immuno-Oncology and …, 2024 - Elsevier
Background Immune-related adverse events (IRAEs) during therapy with immune
checkpoint inhibitors (ICIs) are common, and their management sometimes requires …
checkpoint inhibitors (ICIs) are common, and their management sometimes requires …
Prognosis of patients developing immune-related adverse events with immune checkpoint inhibitors in melanoma influenced by the ability to resume therapy.
61 Background: Immune checkpoint inhibitors (ICPis) have improved survival in melanoma
patients, however their use is associated with 5-60% patients experiencing severe immune …
patients, however their use is associated with 5-60% patients experiencing severe immune …
Association of immune-related adverse event management with survival in patients with advanced melanoma
OJ Van Not, RJ Verheijden… - JAMA …, 2022 - jamanetwork.com
Importance Management of checkpoint inhibitor–induced immune-related adverse events
(irAEs) is primarily based on expert opinion. Recent studies have suggested detrimental …
(irAEs) is primarily based on expert opinion. Recent studies have suggested detrimental …